Cargando…

Kinase Inhibitor Sorafenib Modulates Immunosuppressive Cell Populations in a Murine Liver Cancer Model

Accumulating evidence suggests that regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC) are elevated in cancer patients and tumor-bearing hosts, and that depletion of Tregs and MDSC may enhance the anti-tumor immunity of the host. Sorafenib, a novel multikinase inhibitor, is appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Mengde, Xu, Yiling, Youn, Je-in, Cabrera, Roniel, Zhang, Xiaokui, Gabrilovich, Dmitry, Nelson, David R., Liu, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711234/ https://www.ncbi.nlm.nih.gov/pubmed/21321535 http://dx.doi.org/10.1038/labinvest.2010.205

Ejemplares similares

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021)

New roles of Rb1 in expansion of MDSCs in cancer
por: Youn, Je-In, et al.
Publicado: (2013)

Rare Case of Adult Undifferentiated (Embryonal) Sarcoma of the Liver Treated with Liver Transplantation: Excellent Long-Term Survival
por: Dhanasekaran, Renumathy, et al.
Publicado: (2012)

Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer
por: Cerquetti, Lidia, et al.
Publicado: (2021)

Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis
por: Pesce, Antonio, et al.
Publicado: (2020)

Loss of Rb1 by epigenetic modification regulates expansion of MDSC in cancer
por: Youn, Je-In, et al.
Publicado: (2014)

Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib
por: Ross, Fiona A., et al.
Publicado: (2017)

Correlative studies of a Phase II clinical study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma
por: Yopp, Adam, et al.
Publicado: (2014)

Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
por: Karovic, S, et al.
Publicado: (2016)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation
por: Ismael, Media N., et al.
Publicado: (2019)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Sorafenib as an Inhibitor of RUVBL2
por: Nano, Nardin, et al.
Publicado: (2020)

Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
por: Sun, Weijing, et al.
Publicado: (2018)

Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib
por: Weng, Xie, et al.
Publicado: (2019)

Disease monitoring of hepatocellular carcinoma through metabolomics
por: Fitian, Asem I, et al.
Publicado: (2017)

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
por: Dhanasekaran, Renumathy, et al.
Publicado: (2012)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment
por: Wang, Yuehua, et al.
Publicado: (2022)

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2023)

Differential effects of the immunosuppressive calcineurin inhibitors cyclosporine-A and tacrolimus on ovulation in a murine model
por: Zakerkish, F, et al.
Publicado: (2021)

Fatal attraction: How macrophages participate in tumor metastases
por: Gabrilovich, Dmitry
Publicado: (2015)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters
por: Hsieh, Chen-Hsi, et al.
Publicado: (2020)

Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells
por: Iyer, Renuka V., et al.
Publicado: (2019)

Modulation of Autophagy by Sorafenib: Effects on Treatment Response
por: Prieto-Domínguez, Nestor, et al.
Publicado: (2016)

Kinase Inhibitor Library Screening Identifies the Cancer Therapeutic Sorafenib and Structurally Similar Compounds as Strong Inhibitors of the Fungal Pathogen Histoplasma capsulatum
por: Berkes, Charlotte, et al.
Publicado: (2021)

Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
por: Llerena, Susana, et al.
Publicado: (2018)

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges
por: Schneider, Tatiana C., et al.
Publicado: (2016)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Romito, Ilaria, et al.
Publicado: (2021)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
por: Wang, Li, et al.
Publicado: (2019)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
por: Sangro, Bruno, et al.
Publicado: (2012)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib
por: Zhang, Rui, et al.
Publicado: (2019)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t08s22icqgmdr3kg4ul9u7mnap